#CDKinhibitor - Twitter Hashtag

about 2 years ago

Genentech has entered into an agreement with Regor Pharmaceuticals to acquire its next-generation CDK inhibitors for the treatment of breast cancer. @genentech #Genentech #RegorPharmaceuticals #CDKinhibitor #breastcancertreatment #pharmamanufacturing https://t.co/XrboqoKvBi

PharmaMfg's tweet photo. Genentech has entered into an agreement with Regor Pharmaceuticals to acquire its next-generation CDK inhibitors for the treatment of breast cancer.

@genentech #Genentech #RegorPharmaceuticals #CDKinhibitor #breastcancertreatment #pharmamanufacturing

https://t.co/XrboqoKvBi https://t.co/7RBy1SsVqx

0

2

0

108

alfred fischer @alfredfischer17

over 2 years ago

Die Monarch 3 (mit Abemaciclib) am Ende auch nicht signifikant. #brustkrebs #cdkinhibitor #mammacarcinoma #breastcancer

Yakup Ergün

@dr_yakupergun

over 2 years ago

MONARCH 3: Final overall survival results 🔍mFU: 8.1 years (OS: secondary endpoint) mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06) 💥The absolute difference was 13.1 months but did not reach statistical significance @Annals_Oncology @OncoAlert https://t.co/EPZmdPNsBo

dr_yakupergun's tweet photo. MONARCH 3: Final overall survival results

🔍mFU: 8.1 years (OS: secondary endpoint)

mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06)

💥The absolute difference was 13.1 months but did not reach statistical significance

@Annals_Oncology @OncoAlert
https://t.co/EPZmdPNsBo https://t.co/QBohEOxE26

2

122

45

24

51K

0

2

0

152

The Oncologist @OncJournal

over 2 years ago

In the #KENDO trial, there was no benefit from using 1L/2L #chemo vs #CDKinhibitor +��endocrine therapy in chemo-naïve patients with aggressive HR+/HER2– metastatic #BreastCancer. #bcsm @FrancescoSche20 @hospitalclinic @UgoDeGiorgi @IRSTDinoAmadori https://t.co/okxRYuw4A7

OncJournal's tweet photo. In the #KENDO trial, there was no benefit from using 1L/2L #chemo vs #CDKinhibitor +��endocrine therapy in chemo-naïve patients with aggressive HR+/HER2– metastatic #BreastCancer. #bcsm @FrancescoSche20 @hospitalclinic @UgoDeGiorgi @IRSTDinoAmadori
https://t.co/okxRYuw4A7 https://t.co/upb2cMB2se

0

3

2

0

913

HemaSphere Journal (prelim IF = 11.3)

@Hemasphere_EHA

over 5 years ago

What's the treatment future of mature #TcellLeukemias?Read this new perspective 👉 https://t.co/dcr0nleit7 #TPLL #BCL2 #HDACinhibitor #CDKinhibitor #CART #leusm

Hemasphere_EHA's tweet photo. What's the treatment future of mature #TcellLeukemias?Read this new perspective 👉 https://t.co/dcr0nleit7

#TPLL #BCL2 #HDACinhibitor #CDKinhibitor #CART #leusm https://t.co/IsVdcSBYU6

0

3

0

ecancer @ecancer

about 6 years ago

Researchers reveal discovery of new cancer drug #fadraciclib. Read more here: https://t.co/5kkiRwfr4b @ICR_London @PLOSONE #TargetedTherapy #ClinicalTrials #CDKInhibitor #Oncology #CancerResearch

ecancer's tweet photo. Researchers reveal discovery of new cancer drug #fadraciclib.
Read more here: https://t.co/5kkiRwfr4b
@ICR_London @PLOSONE
#TargetedTherapy #ClinicalTrials #CDKInhibitor #Oncology #CancerResearch https://t.co/m65zdtec9l

0

3

2

0

EMBO Mol. Medicine @EmboMolMed

over 6 years ago

AR Paliouras, M Buzzetti, M Garofalo and colleagues @CRUK_MI report on #CDKinhibitor as an alternative treatment for #ALKinhibitor-resistant #lungcancer https://t.co/YSIk7UclbG

EmboMolMed's tweet photo. AR Paliouras, M Buzzetti, M Garofalo and colleagues @CRUK_MI report on #CDKinhibitor as an alternative treatment for #ALKinhibitor-resistant #lungcancer

https://t.co/YSIk7UclbG https://t.co/XRbQIhaUsl

0

10

5

0

𝕊𝕦𝕤𝕒𝕟 𝕄𝕖𝕝𝕚𝕒 @SueMel29

about 7 years ago

Off we go - starting tomorrow on my 8th line of treatment for #mbc Let’s hope we see some benefit from #abemaciclib (Verzenio)and #letrozole combo. It’s a long shot going back to a #CDKinhibitor after #ibrance but I’m willing to try #outofgoodoptionsanyway #onward #hope

17

48

0